LTB4R and exocrine pancreatic carcinoma: However, a randomized double-blind phase II trial revealed that combining BLT-1 antagonist LY293111 and gemcitabine did not add any benefit in terms of survival to chemotherapy-naïve patients with advanced pancreatic carcinoma [30].